


AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A follicle stimulating hormone peptide conjugate comprising a follicle stimulating hormone peptide and at least one moiety having the formula:



wherein

D is ~~a member selected from~~ -OH and or R^1 -L-HN-;

G is ~~a member selected from~~ R^1 -L- and or -C(O)(C₁-C₆)alkyl;


R^1 is a moiety comprising ~~a member selected a moiety comprising~~ a straight-chain or branched poly(ethylene glycol) residue; and

L is a linker ~~which is a member~~ selected from the group consisting of a bond, substituted ~~or~~ and unsubstituted ~~alkyl~~ alkyls, and substituted ~~or~~ and unsubstituted ~~heteroalkyl~~ heteroalkyls,

such that when D is ~~OH~~ -OH, G is R^1 -L-, and when G is -C(O)(C₁-C₆)alkyl, D is R^1 -L-NH-; and

wherein the moiety is covalently attached to the follicle stimulating hormone peptide via an intact glycosyl linking group.


2. (Previously Presented) The peptide conjugate according to claim 1, wherein R^1 -L has the formula:



wherein

a is an integer from 0 to 20.

3. (Previously Presented) The peptide conjugate according to claim 1, wherein R¹ has a structure that is a member selected from:






wherein


e and f are integers independently selected from 1 to 2500; and

q is an integer from 0 to 20.

4. (Previously Presented) The peptide conjugate according to claim 1, wherein R¹ has a structure that is a member selected from:



and





wherein

e, f and f' are integers independently selected from 1 to 2500; and

q and q' are integers independently selected from 1 to 20.

5. (Previously Presented) The peptide conjugate according to claim 1, wherein R¹ has a structure that is a member selected from:





wherein

e, f and f' are integers independently selected from 1 to 2500; and

q, q' and q'' are integers independently selected from 1 to 20.


6. (Withdrawn) The peptide conjugate according to claim 1, wherein R¹ has a structure that is a member selected from:



wherein


e and f are integers independently selected from 1 to 2500.

7. (Previously Presented) The peptide conjugate according to claim 1, wherein said moiety has the formula:



8. (Previously Presented) The peptide conjugate according to claim 1, wherein said peptide has an amino acid sequence selected from SEQ ID NO:1 and SEQ ID NO:2.

9. (Currently Amended) The peptide conjugate according to claim 1, wherein said moiety has the formula:



wherein

a, b, c, d, i, r, s, t, and u are integers independently selected from 0 and 1, and at least one of r, s, t, and u is 1;

q is 1;


e, f, g, and h are members independently selected from the integers from 0 to 6;

j, k, l, and m are members independently selected from the integers from 0 and 100;

v, w, x, and y are independently selected from 0 and 1, and least one of v, w, x and y is 1;

AA is an amino acid residue of said FSH peptide; and

Sia-(R) has the formula:



10. (Previously Presented) The peptide conjugate according to claim 9, wherein said amino acid residue is an asparagine residue.

11. (Previously Presented) The peptide conjugate according to claim 10, wherein said amino acid residue is an asparagine residue selected from N7 of SEQ ID NO:2, N24 of SEQ ID NO:2, N52 of SEQ ID NO:1, and N78 of SEQ ID NO:1.

12. (Previously Presented) The peptide conjugate according to claim 1, wherein said peptide is a bioactive follicle stimulating hormone peptide.

13.-20. (Canceled)

21. (Withdrawn – Currently Amended) A method of stimulating ovarian follicles in a mammal, ~~said method comprising~~ wherein the method comprises administering to said a mammal in need thereof the peptide conjugate according to claim 1 to stimulate ovarian follicles in the mammal.

22. (Withdrawn – Currently Amended) A method of treating ~~a condition~~ reproductive infertility in a subject, ~~wherein the method comprises in need thereof, said condition characterized by reproductive infertility said method comprising the step of~~ administering to ~~the~~ a subject in need thereof an effective amount of the peptide conjugate according to claim 1 ~~1, effective to ameliorate said condition in said~~ reproductive infertility in the subject.

23. (Previously Presented) A pharmaceutical formulation comprising the peptide conjugate according to claim 1, and a pharmaceutically acceptable carrier.

24. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 2, and a pharmaceutically acceptable carrier.

25. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 3, and a pharmaceutically acceptable carrier.

26. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 4, and a pharmaceutically acceptable carrier.

27. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 5, and a pharmaceutically acceptable carrier.

28. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 6, and a pharmaceutically acceptable carrier.

29. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 7, and a pharmaceutically acceptable carrier.

30. (New) A pharmaceutical formulation comprising the peptide conjugate according to claim 9, and a pharmaceutically acceptable carrier.